[go: up one dir, main page]

BR9813020A - Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos - Google Patents

Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos

Info

Publication number
BR9813020A
BR9813020A BR9813020-0A BR9813020A BR9813020A BR 9813020 A BR9813020 A BR 9813020A BR 9813020 A BR9813020 A BR 9813020A BR 9813020 A BR9813020 A BR 9813020A
Authority
BR
Brazil
Prior art keywords
compounds
derivatives
drugs containing
lysophosphatidylic acid
acid
Prior art date
Application number
BR9813020-0A
Other languages
English (en)
Inventor
Angelika Esswein
Lothar Kling
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BR9813020A publication Critical patent/BR9813020A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<B><MU>UTILIZAçãO DE DERIVADOS DE áCIDO LISOFOSFATIDìLICO, COMPOSTOS E DROGAS QUE CONTêM ESSES COMPOSTOS<MV><D> A invenção refere-se a compostos da fórmula (I) em que R^ 1^ = alquila, alquenila ou alquinila tendo de 6 a 24 átomos de carbono; n = 0 - 12; X = oxigênio ou NH; e os sais, ésteres, formas opticamente ativas, racematos e seus derivados que podem ser metabolizados in vivo para produzir compostos da fórmula geral (I), processos de preparação dos mesmos, e drogas que contêm os referidos compostos, para tratamento de distúrbios metabólicos dos ossos.
BR9813020-0A 1997-10-02 1998-09-30 Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos BR9813020A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97117124A EP0906759A1 (de) 1997-10-02 1997-10-02 Neue Osteoblastenspezifische Mitogene: Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1998/006214 WO1999017781A1 (en) 1997-10-02 1998-09-30 Osteoblast-specific mitogens and drugs containing such compounds

Publications (1)

Publication Number Publication Date
BR9813020A true BR9813020A (pt) 2000-08-15

Family

ID=8227430

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813020-0A BR9813020A (pt) 1997-10-02 1998-09-30 Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos

Country Status (16)

Country Link
US (1) US6197759B1 (pt)
EP (2) EP0906759A1 (pt)
JP (2) JP2001518511A (pt)
KR (1) KR100392207B1 (pt)
CN (1) CN1191070C (pt)
AR (1) AR013538A1 (pt)
AT (1) ATE232103T1 (pt)
AU (1) AU738479B2 (pt)
BR (1) BR9813020A (pt)
CA (1) CA2304821C (pt)
DE (1) DE69811253T2 (pt)
DK (1) DK1019062T3 (pt)
ES (1) ES2191350T3 (pt)
TR (1) TR200000875T2 (pt)
WO (1) WO1999017781A1 (pt)
ZA (1) ZA988952B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258730A1 (en) * 2001-11-12 2004-12-23 Yasuhiko Tabata Persistent filmy preparation for topical administration containing prostglandin derivative
AU2003256300A1 (en) 2002-06-24 2004-01-06 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Complexed-acidic-phospholipid-collagen composites for bone induction
KR100789323B1 (ko) * 2005-07-20 2007-12-28 주식회사 엔지켐 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체
US20100266691A1 (en) * 2009-04-15 2010-10-21 Battelle Memorial Institute Agents and Methods to Stimulate Bone Healing
CN113842504B (zh) * 2021-09-22 2022-12-09 苏州大学附属第二医院 一种用于骨再生的多功能电纺支架的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164560A (en) 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
PL151315B1 (pl) * 1987-04-17 1990-08-31 Sposób wytwarzania nowych związków powierzchniowo czynnych
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
ES2094359T3 (es) 1991-06-21 1997-01-16 Genetics Inst Formulaciones farmaceuticas de proteinas osteogenicas.
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
WO1993020859A1 (en) 1992-04-20 1993-10-28 Board Of Regents Of The University Of Washington Sustained release compositions for delivery of growth factors
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
NO940913L (no) 1993-03-26 1994-09-27 Bristol Myers Squibb Co Preparater for kontrollert frigivelse av biologisk aktiv TGF-
EP0625522B1 (en) * 1993-05-18 1998-08-19 Takeda Chemical Industries, Ltd. Benzopyran derivatives and their use
ES2065855B1 (es) * 1993-05-31 1995-09-01 Menarini Lab Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
DE19544635A1 (de) 1995-11-30 1997-06-05 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1019062A1 (en) 2000-07-19
DE69811253D1 (de) 2003-03-13
CA2304821C (en) 2005-08-02
DK1019062T3 (da) 2003-05-26
CN1191070C (zh) 2005-03-02
ZA988952B (en) 2000-04-03
TR200000875T2 (tr) 2000-11-21
KR100392207B1 (ko) 2003-07-23
KR20010030822A (ko) 2001-04-16
JP2001518511A (ja) 2001-10-16
ATE232103T1 (de) 2003-02-15
AU738479B2 (en) 2001-09-20
ES2191350T3 (es) 2003-09-01
CA2304821A1 (en) 1999-04-15
EP0906759A1 (de) 1999-04-07
JP2004217667A (ja) 2004-08-05
US6197759B1 (en) 2001-03-06
DE69811253T2 (de) 2003-12-04
CN1271289A (zh) 2000-10-25
WO1999017781A1 (en) 1999-04-15
AR013538A1 (es) 2000-12-27
EP1019062B1 (en) 2003-02-05
AU1148399A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
DE69604714D1 (de) Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
ES2071725T3 (es) Diesteres fosfato de acido ascorbico y tocoferilo para la inhibicion de la reaccion de maillard.
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
KR940006578A (ko) 2-(3,4-디메톡신나모일) 아미노벤조산
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
ATE103808T1 (de) N-(3,4-dimethoxycinnamoyl)-anthranilsaeure enthaltende arzneimittelzusammensetzungen.
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
ES2098947T3 (es) Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol.
PT101725A (pt) Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem
DE68923151D1 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DE69506197D1 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
BR9813020A (pt) Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos
ES2090703T3 (es) Medicamento agudo que contiene flurbiprofeno y su empleo.
ES2058085T3 (es) Composicion anticonvulsivante que contiene un derivado de aminoacido, y utilizacion de dicho derivado de aminoacido.
IT1306147B1 (it) Derivati di principi attivi ad attivita&#39; terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
FR2712886B1 (fr) Dérivés de 1,3,4-oxadiazol-2(3H)-one, leur préparation et leur application en thérapeutique.
BR9911585A (pt) Compostos derivados a partir de uma alfa-d-xilose, método para a preparação e uso terapêutico
BR9907166A (pt) Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina
AR008764A1 (es) Sales hidratadas de n,n&#39;-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.